Crinetics Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Checking your notes…
Rule 10b5-1 Trading Plans
During the three months ended March 31, 2026, the following members of our Board of Directors and/or officers adopted, modified, terminated a trading arrangement that is intended to satisfy the affirmative defense condition of Rule 10b5-1(c).
| Name | Title of Director or Officer | Action | Date of Action | Duration of Plan | Total Shares of Common Stock to be Sold |
|---|---|---|---|---|---|
| Stephen Betz | Chief Scientific Officer | Adoption of 10b5-1 plan | 2/19/2026 | 2/19/26 - 5/15/2027 | Up to 126,619 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.